Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599456 | 0.89 | SIGMAR1 (0.44) | CNR1CNR2 | |
| SCHEMBL5051915 | 0.82 | CNR1 (0.55) | CNR1CRHR1DPP4 | |
| SCHEMBL3597755 | 0.77 | HRH3 (0.52) | KCNH2HRH1 | |
| SCHEMBL3594803 | 0.76 | HRH3 (0.51) | KCNH2HRH1 | |
| SCHEMBL3602354 | 0.74 | HRH3 (0.55) | KCNH2HRH1 | |
| SCHEMBL3599589 | 0.73 | HRH3 (0.56) | KCNH2HRH1 | |
| SCHEMBL13307847 | 0.70 | CNR1 (0.91) | CNR1CNR2 | |
| SCHEMBL3599212 | 0.69 | CYP1A2 (0.54) | KCNH2HRH1 | |
| SCHEMBL5049373 | 0.68 | CNR1 (0.44) | CNR1CNR2DPP4 | |
| SCHEMBL5049371 | 0.68 | CNR1 (0.49) | CNR1CNR2CRHR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097392-B1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-03-13 | — | — | EP | claimed |
| US-8193223-B2 | 1,2,3-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-05 | — | — | US | claimed |
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. | 2010-01-07 | — | — | US | claimed |
| EP-1921071-A1 | 1,2,3- triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | claimed |
| EP-2097392-B1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-03-13 | — | — | EP | disclosed |
| US-8193223-B2 | 1,2,3-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-05 | — | — | US | disclosed |
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. | 2010-01-07 | — | — | US | disclosed |
| EP-2097392-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055933-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921071-A1 | 1,2,3- triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, OPRK1, OPRD1 | CNR1 24/4885CNR2 61/4885CRHR1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.